Oncolytics Biotech entered into $50M at-the-market sales agreement with BTIG

Oncolytics Biotech (NASDAQ:ONCY [https://seekingalpha.com/symbol/ONCY]) has established a new at-the-market equity financing agreement with BTIG, LLC. As disclosed in a Securities and Exchange Commission (SEC) filing [https://seekingalpha.com/filing/10537630] on October 17, 2025, the deal allows Oncolytics Biotech to sell up to $50 million worth of its common stock to the public through BTIG, which will act as the sales agent.

Under the terms of the ATM agreement, BTIG will sell shares directly into the market at prevailing market prices over time.

This arrangement provides Oncolytics with a non-dilutive, flexible, and efficient method of raising capital as needed to fund ongoing operations, research, and development.

MORE ON ONCOLYTICS BIOTECH

* Seeking Alpha’s Quant Rating on Oncolytics Biotech [https://seekingalpha.com/symbol/ONCY/ratings/quant-ratings]
* Historical earnings data for Oncolytics Biotech [https://seekingalpha.com/symbol/ONCY/earnings]
* Financial information for Oncolytics Biotech [https://seekingalpha.com/symbol/ONCY/income-statement]